Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Myelofibrosis Clinical Trial

— PRIME  

Official title:

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With Myelofibrosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01693601
• Other study ID #: GCO 12-1225
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 2013
• Est. completion date: May 18, 2018

Study information

• Verified date: October 2023
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.

Description:

Phase I/II open label, single institution, combination therapy trial of induction Ruxolitinib followed by combination with Panobinostat in dose escalation cohorts with a primary endpoint of determining the safety and tolerability of combination therapy in patients with myelofibrosis (MF) in chronic and accelerated phase. A 3+3standard dose escalation scheme will be employed and the occurrence of dose limiting toxicities (DLTs) will be captured and the occurrence of such events will determine dose cohort escalation by predetermined and established rules. In addition to establishing the DLTs, maximally tolerated dose (MTD), and recommended phase II dose (RPTD) in the phase I portion of this trial, exploratory biomarkers will be evaluated within phase I as well. Pharmacodynamics and exploratory genetic and epigenetic biomarkers will be explored as predictors of response to therapy. The RPTD cohort will be expanded to incorporate a total of 22 patients, including 6 from phase I, in order to assess clinical response as assessed by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) as a primary endpoint for the phase II portion of this trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: May 18, 2018
• Est. primary completion date: May 18, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients aged = 18 years old

• Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

• Intermediate-2 and higher by IWG-MRT Post PV/ET MF and PMF patients either in

1. Chronic Phase (MF-CP)

2. Accelerated Phase (MF-AP)

• Patients must meet the following laboratory criteria:

1. ANC = .750 x 109/L

2. Platelets = 75 x 109/L

3. Creatinine = 1.5 x ULN,

4. AST and ALT = 2.5 x ULN

5. Serum bilirubin = 1.5 x ULN (unless Gilbert's syndrome and evidence of hemolysis)

6. Serum potassium = LLN

7. Total serum calcium [corrected for serum albumin] or ionized calcium =LLN,

8. Serum magnesium = LLN

9. Serum phosphorus = LLN

10. Free T4 within normal limits

• ECOG Performance Status of = 3

• Any prior therapy with JAK2-TKI, hypomethylating agents, HDACI, mTORi, or iMiDs is allowed as long as it is greater than 3 weeks since last dose of administration and in the case of a JAK2-TKI or HDACI that discontinuation was not due to non-hematologic drug toxicity. An exception to this criteria are patients currently on at least 10mg BID of ruxolitinib for greater than 3 months and who have not shown an optimal response (i.e. without 50% reduction in palpable splenomegaly or 50% reduction in symptom burden). With a reduction of ruxolitinib to 10mg BID these patients may enter onto the study without stopping ruxolitinib

Exclusion Criteria:

• Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANOBINOSTAT treatment.

• Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

1. With permanent cardiac pacemaker

2. Resting bradycardia defined as <50 beats per minute

3. QTcF >450 msec on screening ECG

4. Complete Left bundle branch block, bifascicular block

5. Any clinically significant ST segment and/or T-wave abnormalities

6. Presence of unstable atrial fibrillation (ventricular response rate >100 bpm). Patients with stable atrial fibrillation can be enrolled provided they do not meet other cardiac exclusion criteria.

7. Symptomatic congestive heart failure (NYHA class III-IV)

• Impairment of GI function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB

• Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol

• Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug

• Concomitant use of CYP3A4 inhibitors

• Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies.

• Chemotherapy within 3 weeks prior to screening are excluded (other than hydroxyurea at stable doses and will be discontinued 24 hours prior to starting study drug).

• Patients with an active bleeding tendency or are receiving any treatment with therapeutic doses of sodium warfarin (Coumadin®) or coumadin derivatives. Patients will be allowed to enter study on aspirin at doses of 81mg/d.

• Patients who have undergone major surgery = 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

• Women who are pregnant or breast-feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential must have a negative serum pregnancy test within 24hrs of receiving the first dose of study medication.

• Male patients whose sexual partners are WOCBP not using effective birth control

• Patients with a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)

• Disease associated with secondary MF such as metastatic carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease or acute leukemia (including M7 disease or acute panmyelosis with MF)

Related Conditions & MeSH terms

• Myelofibrosis
• Primary Myelofibrosis

Intervention

Drug:
• Panobinostat
PO TIW QOW or PO TIW QW
• Ruxolitinib
PO BID x 28 days

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
John Mascarenhas

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, El Jamal S, Petersen B, Moshier E, Hoffman R. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and pos — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients That Achieve Stable Disease or Clinical Improvement	Number of patients that have either stable disease or clinical improvement treatment response as defined by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).; Stable disease (SD) - response that is not complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, or progressive disease.; Clinical improvement (CI) - a response in anemia, splenomegaly, or MF-SB that is not associated with progressive splenomegaly or increase in severity of anemia, thrombocytopenia, or neutropenia.	at least 6 months
Primary	Number of Participants Who Experienced Dose-Limiting (DLTs)	Panobinostat related adverse events requiring dose reduction or discontinuing prior to Cycle 6, Day 29 (C6D29)	up to cycle 6, day 29
Secondary	Percent Change in Spleen Volume	Percent change in spleen volume at C6D29 as compared to baseline	Baseline and Cycle 6, Day 29
Secondary	Percent Change in Spleen Size for Responders and Non-responders	Percent change in spleen length size by palpation at cycle 6, day 29 (C6D29) from baseline	Cycle 6, Day 29
Secondary	Percent Change in Spleen Length	Percent change in spleen length at C6D29	Cycle 6, Day 29
Secondary	Number of Participants With Percent Change on Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)	Symptom responders defined as having a percent change in MPN-SAF score from Screening/C1D1 to C6D29 of more than 50%.MPN-SAF is an 18-item instrument. Each item score 0-10 averaged, total scale from0-10, with higher score indicating more symptoms.	baseline, C1D1 and Cycle 6 Day 29